TheraRadar
Clinical-Stage Companies / Kedrion

Kedrion

Pre-Approval PRO BETA
9
Total Trials
8
Phase 3
1
Phase 2
4
Recruiting
148
Score

Pipeline by Phase

Phase 3
8
Phase 2
1
Phase 1

Therapeutic Focus

Primary Immunodeficiency Disease Chronic Inflammatory Demyelinating Polyneuropathy Chronic Primary Immune Thrombocytopenia (ITP) Acquired Factor X Deficiency Hypovolemia

Clinical Trials (9)

NCT06752356 Phase 3 RECRUITING

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Started: 4/1/2026

NCT07059000 Phase 3 RECRUITING

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Started: 8/13/2025

NCT06963216 Phase 3 RECRUITING

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Started: 2/1/2026

NCT04944979 Phase 3 ACTIVE NOT RECRUITING

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

Started: 3/31/2021

NCT03961009 Phase 3 COMPLETED

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

Started: 4/30/2019

NCT01581593 Phase 3 COMPLETED

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Started: 11/12/2012

NCT07552987 Phase 3 NOT YET RECRUITING

A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome

Started: 9/1/2026

NCT01554956 Phase 2 COMPLETED

Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients

Started: 5/22/2013

NCT01531803 Phase 4 TERMINATED

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

Started: 2/5/2015

Drug Candidates

Immune globulin (human) 10% solution for intravenous administration Kedrion IVIG 10% Coagadex(R) Kedbumin 25% Normal Saline Solution Human Plasminogen Kedrion IVIg 10% Human Albumin 5%
Activity Status: Active
Last Trial Started: 9/1/2026
Last Trial Ended: 12/21/2020
Trials (12 months): 4
Completed Trials: 3
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.